AMRX
Amneal Pharmaceuticals, Inc.
$13.71
-0.29%
$4.4B
No data for this timeframe.
Vol
Market Cap$4.4B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (91%)
Inst. Holders9 funds
Inst. Value$341.2M
Inst. Activity5 buys / 2 sells
Insider Activity0B / 1S
Insider Net $-$450.6K
Reddit Sentiment33° Cool
SEC Reports5
Recent Activity
Jun 5, 2026
other
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
<p align="left">BRIDGEWATER, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc.
May 29, 2026
Event
Warfarin Sodium
WARNING: BLEEDING RISK Warfarin sodium can cause major or fatal bleeding [see Warnings and Precautio
May 11, 2026
Insider
Autor Deborah M. sold 34,819 shares
Director @ $12.94 ($450.6K)
May 7, 2026
SEC
Amneal Pharmaceuticals reported Q1 2026 adjusted EPS of $0.27, beating consensus of $0.17 by 58.8%, and revenue of $723M
PRESS-RELEASE — Impact 8/10
May 7, 2026
Insider
Yanai Shlomo sold 34,819 shares
Director @ $0.00 ($0.00)
May 7, 2026
Insider
Yanai Shlomo sold 34,819 shares
Director @ $0.00 ($0.00)
Apr 22, 2026
SEC
Amneal Pharmaceuticals reported strong preliminary Q1 2026 results with revenue of $723M (4% YoY growth) and adjusted di
PRESS-RELEASE — Impact 9/10
Apr 7, 2026
SEC
Amneal Pharmaceuticals announced it will release Q1 2026 financial results on May 1, 2026, with no updated financials pr
PRESS-RELEASE — Impact 3/10
Price Targets
$17.20
+17.1% upside
Buy
Current $14.69
Low $16.00
Median $17.00
High $19.00
5 analysts
$16.00
$19.00
Analyst Ratings
2Strong Buy
8Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 20, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| Apr 17, 2026 | UBS | INITIATE | Buy |
| Mar 2, 2026 | Truist Securities | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $0.23 ▲ +0.8% | $0.21 — $0.26 | -7% YoY | 6 |
| Next Q | $0.26 ▼ -8.3% | $0.22 — $0.29 | 50% YoY | 6 |
| Current FY | $0.99 ▼ -0.6% | $0.94 — $1.01 | 19% YoY | 6 |
| Next FY | $1.13 ▼ -4.3% | $1.04 — $1.20 | 14% YoY | 6 |
Latest Reports
BULLISH
PRESS-RELEASE
8/10
Amneal Pharmaceuticals reported Q1 2026 adjusted EPS of $0.27, beating consensus of $0.17 by 58.8%, and revenue of $723M
May 7, 2026
BULLISH
PRESS-RELEASE
9/10
Amneal Pharmaceuticals reported strong preliminary Q1 2026 results with revenue of $723M (4% YoY growth) and adjusted di
Apr 22, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $225.6M | — |
| MORGAN STANLEY | $60.7M | ADD |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $27.0M | NEW |
| NORGES BANK | $11.2M | NEW |
| BANK OF AMERICA CORP | $5.7M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 11, 2026 | Autor Deborah | SELL | $450.6K |
| May 7, 2026 | Yanai Shlomo | M | $0.00 |
| May 7, 2026 | Yanai Shlomo | M | $0.00 |
| May 7, 2026 | MEISTER PAUL | M | $0.00 |
| May 7, 2026 | Nark Ted | M | $0.00 |
Reddit Sentiment
33°
Cool
Bearish
Neutral
Bullish
9 institutional holders with $341.2M total value (27,078,171 shares) as of 2025-Q4. Top holders: VANGUARD, MORGAN, CHARLES. Net buying activity: 5 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 17,907,815 | $225.6M | 66.1% | — |
| 2 | MORGAN STANLEY | 4,818,099 | $60.7M | 17.8% | ADD +37.5% |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2,144,471 | $27.0M | 7.9% | NEW |
| 4 | NORGES BANK | 889,500 | $11.2M | 3.3% | NEW |
| 5 | BANK OF AMERICA CORP /DE/ | 451,158 | $5.7M | 1.7% | TRIM -31.9% |
| 6 | FMR LLC | 377,024 | $4.8M | 1.4% | ADD +28.4% |
| 7 | TWO SIGMA INVESTMENTS, LP | 301,028 | $3.8M | 1.1% | DOUBLED +332.9% |
| 8 | WELLS FARGO & COMPANY/MN | 172,676 | $2.2M | 0.6% | ADD +80.0% |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 16,400 | $206.6K | 0.1% | NEAR_EXIT -81.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | ADD | 3,503,081 | 4,818,099 | +37.5% | $60.7M | 2025-Q4 |
| NORGES BANK | NEW | — | 889,500 | — | $11.2M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 662,895 | 451,158 | -31.9% | $5.7M | 2025-Q4 |
| FMR LLC | ADD | 293,571 | 377,024 | +28.4% | $4.8M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 69,534 | 301,028 | +332.9% | $3.8M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 95,915 | 172,676 | +80.0% | $2.2M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 89,900 | 16,400 | -81.8% | $206.6K | 2025-Q4 |
| MORGAN STANLEY | ADD | 2,497,233 | 3,503,081 | +40.3% | $35.1M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 428,000 | 89,900 | -79.0% | $899.9K | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 17,745 | 69,534 | +291.9% | $696.0K | 2025-Q3 |
| MORGAN STANLEY | ADD | 1,621,001 | 2,497,233 | +54.1% | $20.2M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 624,700 | 428,000 | -31.5% | $3.5M | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | NEAR_EXIT | 167,700 | 17,745 | -89.4% | $143.6K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 167,700 | — | $1.4M | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 21,773,049 | 1,665,525 | -92.4% | $13.2M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 177,835 | 77,973 | -56.2% | $617.5K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,404,883 | — | $11.7M | 2024-Q3 |
14 unique insiders with 1 transactions. Net insider value: -$450.6K ($0.00 bought, $450.6K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 11, 2026 | Autor Deborah M. | Director | SELL | 34,819 | $12.94 | $450.6K |
| May 7, 2026 | Yanai Shlomo | Director | M | 34,819 | $0.00 | $0.00 |
| May 7, 2026 | Yanai Shlomo | Director | M | 34,819 | $0.00 | $0.00 |
| May 7, 2026 | MEISTER PAUL M | Director | M | 48,747 | $0.00 | $0.00 |
| May 7, 2026 | Nark Ted C | Director | M | 34,819 | $0.00 | $0.00 |
| May 7, 2026 | MEISTER PAUL M | Director | M | 48,747 | $0.00 | $0.00 |
| May 7, 2026 | Nark Ted C | Director | M | 34,819 | $0.00 | $0.00 |
| May 7, 2026 | Kiely John | Director | M | 34,819 | $0.00 | $0.00 |
| May 7, 2026 | Kiely John | Director | M | 34,819 | $0.00 | $0.00 |
| May 7, 2026 | Patel Gautam | Director | M | 34,819 | $0.00 | $0.00 |
| May 7, 2026 | Patel Gautam | Director | M | 34,819 | $0.00 | $0.00 |
| May 7, 2026 | George Jeffrey P. | Director | M | 34,819 | $0.00 | $0.00 |
| May 7, 2026 | George Jeffrey P. | Director | M | 34,819 | $0.00 | $0.00 |
| May 7, 2026 | Autor Deborah M. | Director | M | 34,819 | $0.00 | $0.00 |
| May 7, 2026 | Autor Deborah M. | Director | M | 34,819 | $0.00 | $0.00 |
| May 7, 2026 | BUCHI J KEVIN | Director | M | 34,819 | $0.00 | $0.00 |
| May 7, 2026 | BUCHI J KEVIN | Director | M | 34,819 | $0.00 | $0.00 |
| May 6, 2026 | BUCHI J KEVIN | Director | A | 19,824 | $0.00 | $0.00 |
| May 6, 2026 | Autor Deborah M. | Director | A | 19,824 | $0.00 | $0.00 |
| May 6, 2026 | George Jeffrey P. | Director | A | 19,824 | $0.00 | $0.00 |
| May 6, 2026 | Patel Gautam | Director | A | 19,824 | $0.00 | $0.00 |
| May 6, 2026 | Kiely John | Director | A | 19,824 | $0.00 | $0.00 |
| May 6, 2026 | Nark Ted C | Director | A | 19,824 | $0.00 | $0.00 |
| May 6, 2026 | MEISTER PAUL M | Director | A | 30,837 | $0.00 | $0.00 |
| May 6, 2026 | Yanai Shlomo | Director | A | 19,824 | $0.00 | $0.00 |
| Mar 4, 2026 | Patel Chintu | Co-CEO | M | 92,593 | $0.00 | $0.00 |
| Mar 4, 2026 | Patel Chintu | Co-CEO | M | 92,593 | $0.00 | $0.00 |
| Mar 4, 2026 | Patel Chirag K. | President & Co-CEO | M | 92,593 | $0.00 | $0.00 |
| Mar 4, 2026 | Patel Chirag K. | President & Co-CEO | M | 92,593 | $0.00 | $0.00 |
| Mar 4, 2026 | Daly Jason B. | EVP, Chief Legal Officer | M | 35,880 | $0.00 | $0.00 |
| Mar 4, 2026 | Daly Jason B. | EVP, Chief Legal Officer | M | 35,880 | $0.00 | $0.00 |
| Mar 4, 2026 | Konidaris Tasos | Executive Vice President & CFO | M | 43,982 | $0.00 | $0.00 |
| Mar 4, 2026 | Konidaris Tasos | Executive Vice President & CFO | M | 49,982 | $0.00 | $0.00 |
| Mar 4, 2026 | BOYER ANDREW S | Executive Vice President | M | 38,195 | $0.00 | $0.00 |
| Mar 4, 2026 | Shah Nikita | Executive Vice President | M | 35,880 | $0.00 | $0.00 |
| Mar 4, 2026 | BOYER ANDREW S | Executive Vice President | M | 38,195 | $0.00 | $0.00 |
| Mar 4, 2026 | Shah Nikita | Executive Vice President | M | 35,880 | $0.00 | $0.00 |
| Mar 3, 2026 | Patel Chintu | Co-CEO | M | 59,931 | $0.00 | $0.00 |
| Mar 3, 2026 | Patel Chintu | Co-CEO | M | 59,931 | $0.00 | $0.00 |
| Mar 3, 2026 | Patel Chintu | Co-CEO | M | 733,944 | $0.00 | $0.00 |
| Mar 3, 2026 | Patel Chirag K. | President & Co-CEO | M | 59,931 | $0.00 | $0.00 |
| Mar 3, 2026 | Patel Chirag K. | President & Co-CEO | M | 733,944 | $0.00 | $0.00 |
| Mar 3, 2026 | Daly Jason B. | EVP, Chief Legal Officer | M | 22,645 | $0.00 | $0.00 |
| Mar 3, 2026 | Daly Jason B. | EVP, Chief Legal Officer | M | 22,645 | $0.00 | $0.00 |
| Mar 3, 2026 | Daly Jason B. | EVP, Chief Legal Officer | M | 305,810 | $0.00 | $0.00 |
| Mar 3, 2026 | Konidaris Tasos | Executive Vice President & CFO | M | 45,290 | $0.00 | $0.00 |
| Mar 3, 2026 | Konidaris Tasos | Executive Vice President & CFO | M | 458,716 | $0.00 | $0.00 |
| Mar 3, 2026 | BOYER ANDREW S | Executive Vice President | M | 39,252 | $0.00 | $0.00 |
| Mar 3, 2026 | BOYER ANDREW S | Executive Vice President | M | 397,554 | $0.00 | $0.00 |
| Mar 3, 2026 | Shah Nikita | Executive Vice President | M | 366,972 | $0.00 | $0.00 |
5 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 0 mixed, 2 neutral. Avg impact: 6.2/10.
BULLISH
PRESS-RELEASE
8/10
Amneal Pharmaceuticals reported Q1 2026 adjusted EPS of $0.27, beating consensus of $0.17 by 58.8%,
May 7, 2026
BULLISH
PRESS-RELEASE
9/10
Amneal Pharmaceuticals reported strong preliminary Q1 2026 results with revenue of $723M (4% YoY gro
Apr 22, 2026
NEUTRAL
PRESS-RELEASE
3/10
Amneal Pharmaceuticals announced it will release Q1 2026 financial results on May 1, 2026, with no u
Apr 7, 2026
NEUTRAL
DEFA14A
3/10
Amneal Pharmaceuticals, Inc. (AMRX) has filed a definitive proxy statement (DEFA14A) related to a sh
Mar 25, 2026
BULLISH
8-K
8/10
Amneal Pharmaceuticals reported strong Q4 and full-year 2025 results, with revenue up 11% and 8% YoY
Feb 27, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (91% buy). Based on 11 analysts: 2 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$17.20 mean target
+17.1% upside
Buy (1.40)
$16.00 Low
$19.00 High
| Metric | Value |
|---|---|
| Current Price | $14.69 |
| Target Low | $16.00 |
| Target Mean | $17.20 |
| Target Median | $17.00 |
| Target High | $19.00 |
| # Analysts | 5 |
| Recommendation | Buy (1.40) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.23 | $0.21 | $0.26 | -6.7% | +0.8% | 1↑ 1↓ | $0.8B | 5.2% | 6 |
| Next Q 2026-09-30 |
$0.26 | $0.22 | $0.29 | 50.2% | -8.3% | 0↑ 2↓ | $0.8B | 3.3% | 6 |
| Current FY 2026-12-31 |
$0.99 | $0.94 | $1.01 | 19.4% | -0.6% | 1↑ 1↓ | $3.1B | 2.9% | 6 |
| Next FY 2027-12-31 |
$1.13 | $1.04 | $1.20 | 14.3% | -4.3% | 0↑ 3↓ | $3.3B | 7.4% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $0.233 | |
| 7d ago | $0.228 | +0.005 |
| 30d ago | $0.232 | +0.002 |
| 60d ago | $0.234 | -0.000 |
| 90d ago | $0.230 | +0.003 |
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 20, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Apr 17, 2026 | UBS | INITIATE | — | Buy |
| Mar 2, 2026 | Truist Securities | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| May 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| Mar 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| Feb 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% | |
| Jan 1, 2026 | 2 | 8 | 1 | 0 | 0 | 91% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
33°
Cool
Bearish
Neutral
Bullish
2 mentions
0 bullish
2 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 6, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Mar 6, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
Recent Reddit Threads
Jun 5, 2026
other
Amneal Announces Full Study Population Interim Phase 4 ELEVATE-PD Results, Reinforcing Previously Reported Benefits of CREXONT® in Parkinson's Disease
<p align="left">BRIDGEWATER, N.J., June 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), today
May 29, 2026
short_volume
Short Volume: AMRX — 69.8% short (0.4M / 0.6M)
Short: 431,247 | Exempt: 0 | TRF Vol: 617,788 | Short Ratio: 69.8% | Off-exchange volume (dark pool + OTC)
May 29, 2026
FDA
Warfarin Sodium
WARNING: BLEEDING RISK Warfarin sodium can cause major or fatal bleeding [see Warnings and Precautions (5.1) ] . Perform regular monitoring of INR in
May 15, 2026
FDA
OXYCODONE HYDROCHLORIDE
WARNING: ADDICTION, ABUSE AND MISUSE; RISK EVALUATION AND MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; N
May 14, 2026
short_volume
Short Volume: AMRX — 58.3% short (0.3M / 0.6M)
Short: 320,793 | Exempt: 422 | TRF Vol: 550,169 | Short Ratio: 58.3% | Off-exchange volume (dark pool + OTC)
May 13, 2026
FDA
Pyridostigmine bromide
WARNING: RISKS WITH IMPROPER USE OF PYRIDOSTIGMINE BROMIDE After Exposure to Soman, Use Atropine and Pralidoxime Pyridostigmine bromide is for use as
May 12, 2026
FDA
PYRIDOSTIGMINE BROMIDE
Supplemental Approval — Labeling — TABLET, EXTENDED RELEASE
May 7, 2026
earnings
Amneal Reports First Quarter 2026 Financial Results
<p align="center"><em>‒ </em><em>Q1 2026</em><em> Net Revenue of </em><em>$723 million</em><em>; GAAP Net </em><em>Income</em><em> of </em><em>$62 mil
May 1, 2026
earnings_calendar
AMRX Q1 2026 Earnings Scheduled — 2026-05-01
Apr 22, 2026
earnings
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
<p align="center"><em>– Acquisition Positions Amneal to Capitalize on $300B+ Global Biologics LOE Opportunity –</em></p>
Apr 22, 2026
short_volume
Short Volume: AMRX — 78.4% short (0.9M / 1.1M)
Short: 858,631 | Exempt: 35 | TRF Vol: 1,095,807 | Short Ratio: 78.4% | Off-exchange volume (dark pool + OTC)
Apr 17, 2026
short_volume
Short Volume: AMRX — 69.4% short (0.4M / 0.5M)
Short: 379,870 | Exempt: 560 | TRF Vol: 547,170 | Short Ratio: 69.4% | Off-exchange volume (dark pool + OTC)
Apr 14, 2026
other
Amneal Launches First Two Respiratory Metered-Dose Inhalation Products in the U.S.
<p>BRIDGEWATER, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced the
Apr 10, 2026
short_volume
Short Volume: AMRX — 73.6% short (0.4M / 0.6M)
Short: 408,334 | Exempt: 0 | TRF Vol: 554,576 | Short Ratio: 73.6% | Off-exchange volume (dark pool + OTC)
Apr 8, 2026
FDA
traMADol Hydrochloride Tablets, USP, 50 mg, 500-count bottles, Rx only, Manufactured by: Amneal Pharmaceuticals Pvt. Ltd., Ahmedabad 382220, India, Distributed by: Amneal Pharmaceuticals LLC, Glasgow, KY 42141, NDC 60219-2348-5.
Class II: Failed Impurities/Degradation Specifications: N-nitroso-desmethyl-tramadol impurity (NDSRI) was found out of the specification at 24-month s
Apr 7, 2026
earnings
Amneal to Report First Quarter 2026 Results on May 1, 2026
<p>BRIDGEWATER, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), today announced th
Apr 7, 2026
short_volume
Short Volume: AMRX — 72.0% short (0.4M / 0.5M)
Short: 390,189 | Exempt: 0 | TRF Vol: 541,942 | Short Ratio: 72.0% | Off-exchange volume (dark pool + OTC)
Mar 13, 2026
Clinical Trial
Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer
Phase Phase 2 — COMPLETED
Mar 5, 2026
other
Amneal to Participate in Upcoming Investor Conference
<p>BRIDGEWATER, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) today announced that Chirag Patel, Co-Chief Exe
Feb 27, 2026
earnings_calendar
AMRX Q4 2025 Earnings Before Market Open — 2026-02-27
Feb 20, 2026
Clinical Trial
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Phase Phase 2 — TERMINATED
Feb 20, 2026
Clinical Trial
S0125, Chemotherapy, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Older Patients With Acute Myeloid Leukemia
Phase Phase 2 — TERMINATED
Feb 3, 2026
short_interest
FTD: AMRX — 38,390 shares ($0.5M) failed to deliver
Settlement: 20260203, Price: $14.19, FTD Value: $544,754.1, AMNEAL PHARMACEUTICALS INC CL